RallyBio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, a preclinical potentially first-in-class antibody.
ENSEM Therapeutics Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets.
ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing.
Cipia today announced that the company was awarded two new models with a leading Chinese OEM.
Rallybio reports positive data in its clinical program for the prevention of fetal and neonatal alloimuune thrombocytopenia (FNAIT)
Rallybio today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo.